ClinicalTrials.gg
CompletedNCT02960594TRT-001Updated Nov 19, 2018

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

A Phase 1 interventional study of INO-1400 and INO-9012 in Breast Cancer, Lung Cancer and Pancreatic Cancer, sponsored by Inovio Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Inovio Pharmaceuticals · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
93
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.

02

Conditions studied

  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • ColoRectal Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • HepatoCellular Carcinoma

Keywords

  • Immunotherapy
  • Human Telomerase Reverse Transcriptase (hTERT)
  • Breast Neoplasms
  • Lung Neoplasms
  • Pancreatic Neoplasms
  • High Risk of Relapse
  • Post Definitive Surgery
  • Post Adjuvant Therapy
  • No Evidence of Disease
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 93 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Inovio Pharmaceuticals is the lead sponsor of 31 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 10 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Signed and dated written IRB approved ;
    1. Males or females aged ≥18 years;
    1. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitive therapy at the time of signing informed consent as described below for each indication:

      • Breast carcinoma:
      • Lung carcinoma:
      • Pancreatic carcinoma:
      • Head and neck squamous cell carcinoma:
      • Ovarian cancer:
      • Colorectal cancer
      • Gastric and esophageal cancer
      • Hepatocellular carcinoma

Exclusion criteria

Exclusion Criteria:

    1. Previous treatment wth any TERT or IL-12 containing therapy, or any other DNA immunotherapy;
    1. Any concurrent condition requiring the continued or anticipated use of systemic (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or therapy (excludes low dose methotrexate). All other systemic corticosteroids must be discontinued at least 4 weeks prior to first Study Treatment;
    1. Administration of any vaccine within 4 weeks of the first study treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Arm 1

    2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1400

  • Experimental
    Arm 2

    8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1400

  • Experimental
    Arm 3

    2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1400 · Biological: INO-9012

  • Experimental
    Arm 4

    2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1400 · Biological: INO-9012

  • Experimental
    Arm 5

    8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1400 · Biological: INO-9012

  • Experimental
    Arm 6

    8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1400 · Biological: INO-9012

  • Experimental
    Arm 7

    2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1401

  • Experimental
    Arm 8

    8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-1401

  • Experimental
    Arm 9

    8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-9012 · Biological: INO-1401

  • Experimental
    Arm 10

    8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12

    Biological: INO-9012 · Biological: INO-1401

Interventions

  • BiologicalINO-1400

    Also known as: hTERT

  • BiologicalINO-9012

    Also known as: IL-12

  • BiologicalINO-1401

    Also known as: SynCon TERT

06

What researchers measure

Primary outcomes

  1. Adverse events graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03

    Time frame: Up to 2 years from first study treatment

  2. Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration site

    Time frame: Up to 14 weeks

  3. Changes in safety laboratory parameters

    Time frame: Up to 2 years from first study treatment

07

Study locations

6 sites
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15232, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Nov 2018 and a completion of Nov 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2016
First posted
Nov 9, 2016
Start
Dec 2014
Primary completionActual
Nov 9, 2018
CompletionActual
Nov 9, 2018
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02960594
Responsible party
Sponsor
First posted
Nov 9, 2016
Start date
Dec 2014
Primary completion
Nov 9, 2018
Completion
Nov 9, 2018
Last update
Nov 19, 2018

Study contacts

Robert Vonderheide, MD, PhD
principal investigator · University of Pennsylvania
Autumn McRee, MD
principal investigator · University of North Carolina
Jennifer Johnson, MD
principal investigator · Thomas Jefferson University Hospitial
Anthony Shields, MD
principal investigator · Karmanos Cancer Center (Wayne State University)
Nathan Bahary, MD
principal investigator · University of Pittsburgh
Ashish Chintakuntlawar, MBBS, PhD
principal investigator · Mayo Clinic, Rochester, MN

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocakinogene sifuplasmid

Start the discussion